AVMXY - Avita Medical Limited

Other OTC - Other OTC Delayed Price. Currency in USD
6.61
+0.04 (+0.68%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close6.57
Open6.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.51 - 6.80
52 Week Range0.80 - 7.67
Volume65,067
Avg. Volume442,425
Market Cap615.245M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Business Wire11 days ago

    Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System

    AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that the health economic model of the U.S. burn care pathway, developed in collaboration with Biomedical Advanced Research and Development Authority (BARDA) and IQVIA, has been published in the peer-reviewed journal, Advances in Therapy. The model demonstrates that utilizing AVITA Medical’s RECELL® System for the treatment of in-patient burns is cost-saving or cost-neutral and results in reduced length of hospital stay as compared to the standard of care.

  • Business Wire12 days ago

    AVITA Medical Appoints Interim CFO

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced today that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately. Tim Rooney, AVITA’s Chief Administrative Officer, will assume the role of interim CFO until a comprehensive search can be completed. Tim previously served as CFO for AVITA from 2012 to 2017 before assuming his current role.

  • Business Wire25 days ago

    AVITA Medical to Present at RBC Capital Markets 2019 Healthcare Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York. The presentation is being made on 21 May 2019 from 9:00 a.m. to 9:25 a.m. EDT at the InterContinental New York Barclay hotel. AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications.

  • What Kind Of Shareholders Own Avita Medical Limited (ASX:AVH)?
    Simply Wall St.last month

    What Kind Of Shareholders Own Avita Medical Limited (ASX:AVH)?

    The big shareholder groups in Avita Medical Limited (ASX:AVH) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones...

  • Business Wire2 months ago

    AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that interim results describing clinical outcomes for pediatric patients treated using the RECELL® System were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Jeffrey Carter, MD, FACS University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine. Patients enrolled in the Investigational Device Exemption (IDE), Compassionate Use and Continued Access studies had mixed-depth and full-thickness (third-degree) burns and were treated with the combination of Spray-On Skin™ Cells prepared using the RECELL system and widely meshed autografts.

  • Business Wire2 months ago

    AVITA Medical RECELL® System Health Economic Data Project USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced health economic data projecting that use of the RECELL System to treat patients with severe burns could save a major U.S. burn center up to USD $28 million annually compared to treatment with the standard of care. The health economic results were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Kevin Foster, MD, MBA, FACS, of the Arizona Burn Center, and were calculated based on the demographic mix of patients treated at that institution in 2018.

  • Business Wire2 months ago

    AVITA Medical to Present at Cowen and Company Health Care Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at the Boston Marriott Copley Place. AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications.

  • Business Wire3 months ago

    AVITA Medical Announces Ten RECELL® System Presentations at the American Burn Association (ABA) Annual Meeting

    Presentation describing treatment of pediatric patients with RECELL System selected as “Best of the Best Abstract”

  • Business Wire3 months ago

    Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of burns and other wounds in Japan. In addition, COSMOTEC filed on 25 February 2019 a Japan’s Pharmaceuticals and Medical Devices Act (“JPMDA”) application for approval to market the RECELL System in Japan.

  • Business Wire3 months ago

    AVITA Medical Announces Temporary Interruption of Sales of Products in EU

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sales of the RECELL® Device in the EU have been temporarily interrupted. The Company does not actively promote the products in the EU and its activity in the region is limited to filling purchase requests as they are received, therefore the financial impact to AVITA of this temporary interruption is immaterial as EU sales of products have averaged approximately A$40,000 per month during Fiscal 2019. “It is important to note that this interruption is unrelated to the performance and safety of our products and does not impact the U.S. market,” said Dr. Mike Perry, Chief Executive Office of AVITA Medical.

  • Business Wire3 months ago

    Avita Medical Half-Year Financial Report for Fiscal 2019

    AVITA Medical , a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018.

  • Business Wire4 months ago

    AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that 26 abstracts highlighting the clinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been selected for presentation at four burn conferences in early 2019. Nine of the presentations will be made at the largest burn conference, the American Burn Association (ABA) 51st Annual Meeting to be held in Las Vegas April 2-5, 2019, including a Top-Five Abstract presentation in plenary session.

  • Business Wire5 months ago

    AVITA Medical Announces U.S. National Market Launch of RECELL® System

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national market launch of the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of acute thermal burns in patients 18 years and older. The U.S. sales team of Regenerative Tissue Specialists and Clinical Training Specialists that joined AVITA Medical in November 2018 has been trained and fully deployed across the U.S. in support of the nationwide launch of the RECELL System.

  • Business Wire5 months ago

    AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA Medical’s RECELL® Autologous Cell Harvesting System (RECELL System) was selected as part of PM360’s 7th Annual Innovations Issue, which is published in December each year. The RECELL System was approved by the U.S. Food and Drug Administration (FDA) in September 2018 for the treatment of acute thermal burns in patients 18 years and older.

  • Business Wire5 months ago

    AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit

    AVITA Medical , a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018.

  • Business Wire6 months ago

    AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline advancement, and general working capital requirements. Avita has received under the Institutional Placement commitments from U.S., Australian and international institutional and sophisticated investors for a placement of A$40.0 million at an issue price of A$0.080 per share, with the placement to occur in two tranches. Tranche 1 of the institutional placement, totaling A$24.5 million, is expected to settle on 7 December 2018 without the need for prior shareholder approval.

  • Business Wire6 months ago

    AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team of 20 healthcare professionals has joined AVITA and are in the process of completing a rigorous training program, including on-site training within burn centers, in preparation for the market launch of the RECELL System.

  • Business Wire6 months ago

    Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders from five U.S. burn centers presented clinical results of the RECELL® Autologous Cell Harvesting Device (RECELL® System) at two U.S. burn conferences, the 31st Annual Southern Region Burn CME Conference held in Mobile, AL and the Northeast Region Burn Conference held in Cambridge, MA. In addition, the burn surgeons led two medical education symposiums on the use of the RECELL System at the conferences.

  • Business Wire7 months ago

    AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries

    AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a global regenerative medicine company, today announced that the commencement of a randomized, controlled clinical study of the RECELL® Autologous Cell Harvesting Device (RECELL® System) in the treatment of significant superficial partial- and mid-thickness pediatric burns, including scald injuries. The clinical trial is being conducted by the Queensland University of Technology (QUT) in collaboration with the Pegg Leditschke Children’s Burns Centre at Lady Cilento Children’s Hospital in Brisbane, QLD.

  • Business Wire7 months ago

    AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. Food and Drug Administration (FDA) approved on 20 September 2018 the RECELL System to treat acute thermal burns in patients 18 years and older.

  • Business Wire7 months ago

    AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center and Associate Professor of Surgery at LSU Health New Orleans School of Medicine.

  • Business Wire8 months ago

    AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference

    AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) were presented at the 46th Annual Eastern Great Lakes Burn Conference in Ann Arbor, Michigan. The results were presented by Jeffrey Carter, MD, FACS, Medical Director of University Medical Center New Orleans Burn Center & Associate Professor of Surgery at LSU Health New Orleans School of Medicine. “The RECELL System technology provides a major advancement for burn care,” said Dr. Carter.